Press release
B-Cell Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi
B-cell Lymphoma Pipeline Insights
According to DelveInsight, over 295 leading companies are actively engaged in developing more than 300 treatment therapies for B-cell lymphoma.
B-Cell Lymphoma Overview:
B-cell lymphoma is a type of non-Hodgkin lymphoma (NHL) that originates from B lymphocytes, white blood cells that play a key role in producing antibodies to fight infections. Accounting for around 85% of all NHL cases, B-cell lymphomas encompass several subtypes, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma. Although each subtype presents distinct clinical features, they are all characterized by the abnormal proliferation of B-cells within the lymphatic system, commonly impacting the lymph nodes, spleen, and bone marrow.
Request for a detailed insights report on B-Cell Lymphoma pipeline insights [https://www.delveinsight.com/report-store/b-cell-lymphomas-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"B-Cell Lymphoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the B-Cell Lymphoma Therapeutics Market.
Key Takeaways from the B-Cell Lymphoma Pipeline Report
*
DelveInsight's B-Cell Lymphoma pipeline report depicts a robust space with 295+ active players working to develop 300+ pipeline therapies for B-Cell Lymphoma treatment.
*
In May 2023, Bristol Myers Squibb reported positive topline results from two studies: TRANSCEND FL, a global Phase 2, open-label, multicenter, single-arm study of Breyanzi (lisocabtagene maraleucel) in patients with relapsed or refractory follicular lymphoma (FL), and TRANSCEND NHL 001, a pivotal Phase 1, open-label, multicenter, single-arm study of Breyanzi in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL), including mantle cell lymphoma (MCL). Both studies met their primary endpoint of overall response rate, with Breyanzi showing statistically significant and clinically meaningful responses in relapsed or refractory FL and MCL.
*
In May 2023, Janssen Biotech, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture, and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for B-cell malignancies.
*
In May 2023, Genmab A/S announced that the U.S. Food and Drug Administration (FDA) approved EPKINLY Trademark (epcoritamab-bysp), the first and only T-cell engaging bispecific antibody for treating adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma and high-grade B-cell lymphoma, after two or more lines of systemic therapy.
*
In January 2023, Fate Therapeutics, Inc. announced it had declined a proposal from Janssen Biotech, Inc. to continue their collaboration and option agreement under revised terms. As a result, the agreement was terminated, and all collaboration activities were set to wind down by the first quarter of 2023.
*
Key B-Cell Lymphoma companies such as Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi Biomedicine GmbH, AVM Biotechnology, Lin BioScience, Inc, Incyte Corporation, ADC Therapeutics S.A., Genor Biopharma, Beijing InnoCare Pharma Tech Co., Ltd., CARGO Therapeutics, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., SystImmune, LIBO PHARMA, Abclon, BeiGene, Cellectis, Iovance Biotherapeutics, Inc., Guangzhou Excelmab, Y-mAbs Therapeutics, TG Therapeutics, Sutro Biopharma, AbbVie, Aleta Biotherapeutics, Janssen Research & Development, LLC, Lantern Pharma, Beijing Immunochina Medical Science and Technology, Bantam Pharmaceutical, Lin Bioscience, SFA Therapeutics, neoX Biotech, March Biosciences, HUTCHMED, and others are evaluating new drugs for B-Cell Lymphoma to improve the treatment landscape.
*
Promising B-Cell Lymphoma pipeline therapies in various stages of development include Lisocabtagene maraleucel, Glofitamab, NKTR-255, Zamtocabtagene autoleucel, MB-CART20.1, AVM0703, LBS-007, and others.
B-Cell Lymphoma Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the B-Cell Lymphoma Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for B-Cell Lymphoma treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the B-Cell Lymphoma market.
Download our free sample page report on B-Cell Lymphoma pipeline insights [https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
B-Cell Lymphoma Emerging Drugs
*
Lisocabtagene maraleucel: Bristol Myers Squibb
*
Glofitamab: Hoffmann-La Roche
*
NKTR-255: Nektar Therapeutics
*
Zamtocabtagene autoleucel: Miltenyi Biomedicine GmbH
*
MB-CART20.1: Miltenyi Biomedicine GmbH
*
AVM0703: AVM Biotechnology
*
LBS-007: Lin BioScience, Inc
B-Cell Lymphoma Companies
More than 295 prominent companies are currently developing treatments for B-cell lymphoma. Among these, Denovo BioPharma has drug candidates that have reached the most advanced stage-Phase III clinical trials.
DelveInsight's report covers around 295+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
B-Cell Lymphoma Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging B-Cell Lymphoma Therapies and Key Companies: B-Cell Lymphoma Clinical Trials and advancements [https://www.delveinsight.com/report-store/b-cell-lymphomas-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
B-Cell Lymphoma Pipeline Therapeutic Assessment
- B-Cell Lymphoma Assessment by Product Type
- B-Cell Lymphoma By Stage
- B-Cell Lymphoma Assessment by Route of Administration
- B-Cell Lymphoma Assessment by Molecule Type
Download B-Cell Lymphoma Sample report to know in detail about the B-Cell Lymphoma treatment market @ B-Cell Lymphoma Therapeutic Assessment [https://www.delveinsight.com/sample-request/b-cell-lymphomas-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. B-Cell Lymphoma Current Treatment Patterns
4. B-Cell Lymphoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. B-Cell Lymphoma Late-Stage Products (Phase-III)
7. B-Cell Lymphoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. B-Cell Lymphoma Discontinued Products
13. B-Cell Lymphoma Product Profiles
14. B-Cell Lymphoma Key Companies
15. B-Cell Lymphoma Key Products
16. Dormant and Discontinued Products
17. B-Cell Lymphoma Unmet Needs
18. B-Cell Lymphoma Future Perspectives
19. B-Cell Lymphoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the B-Cell LymphomaO Pipeline Reports Offerings [https://www.delveinsight.com/report-store/b-cell-lymphomas-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=bcell-lymphoma-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-lisocabtagene-maraleucel-hoffmannla-roche-nektar-therapeutics-miltenyi]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release B-Cell Lymphoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Lisocabtagene maraleucel, Hoffmann-La Roche, Nektar Therapeutics, Miltenyi here
News-ID: 4100154 • Views: …
More Releases from ABNewswire
BN Canopy Cleaning Marks 15 Years as Melbourne's Leading Canopy Cleaning Special …
BN Canopy Cleaning is celebrating 15 years in business, a milestone that highlights the company's long-standing role in raising hygiene and safety standards for commercial kitchens across Melbourne. Since launching in 2010, BN Canopy Cleaning has grown from a small local operator into one of the city's most established providers of professional canopy cleaning in Melbourne [https://bncanopycleaning.com.au/], trusted by restaurants, hotels, and food service facilities.
From its earliest days, the company…
Presbyopia Pipeline Analysis & Clinical Trials Assessment, 2025, DelveInsight | …
DelveInsight's, "Presbyopia - Pipeline Insight, 2025" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that over 10 key companies are actively engaged in developing…
Macular telangiectasia Pipeline Analysis & Clinical Trials Assessment, 2025, Del …
DelveInsight's, "Macular Telangiectasia (MacTel) Pipeline Insight, 2025," report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Macular Telangiectasia (MacTel) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that more than 4 key companies are…
Corneal ulcer Pipeline Analysis & Clinical Trials Assessment, 2025, DelveInsight …
DelveInsight's, "Corneal Ulcer - Pipeline Insight, 2025," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Corneal Ulcer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
DelveInsight reports that over 15 leading companies are actively engaged…
More Releases for Lymphoma
Lymphoma Treatment Market - Liberating Lives from Lymphoma: State-of-the-Art Tre …
Newark, New Castle, USA: The "Lymphoma Treatment Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Lymphoma Treatment Market: https://www.growthplusreports.com/report/lymphoma-treatment-market/8879
This latest report researches the industry structure, sales, revenue,…
Lymphoma Treatment Market - Inspiring Resilience, Shaping Survival: Innovations …
Newark, New Castle, USA - new report, titled Lymphoma Treatment Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Lymphoma Treatment market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Lymphoma Treatment market. The report offers an overview of the market, which…
Lymphoma Therapeutics Market: New Frontiers in Lymphoma Therapeutics | By AMR
Allied Market Research recently said Lymphoma is a type of cancer that affects the lymphatic system, which is an integral part of the body's immune system. While chemotherapy and radiation therapy have been the standard treatment options for lymphoma, recent advances in research have led to the development of new targeted therapies and immunotherapies.
♦ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/request-toc-and-sample/1448
One such targeted therapy is monoclonal antibodies, which can specifically target…
Daratumumab Market Precise Analysis , Forecast || key Players- Multiple Myeloma, …
Looking at the current market trends as well as the promising demand status of the “Daratumumab Market”, it can be projected that the future years will bring out positive outcomes. This research report added by Market Research Hub (MRH) on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application;…
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. T-Cell Lymphoma Market Analysis
2. Mechanism of T-Cell Lymphoma Therapeutics
3. T-Cell Lymphoma Drug Market Overview
3.1 Current Market Scenario
3.2 T Cell Lymphoma Clinical Pipeline Overview
4. T-Cell Lymphoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges
5. T-Cell Lymphoma Drug Market Future Prospects
6. T-Cell Lymphoma Drug Clinical Pipeline By Company…
B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to B Cell Lymphoma
1.1 Outline
1.1.1 Non-Hodgkin’s Lymphoma
1.1.2 Hodgkin’s Lymphoma
1.2 Classification of the B Cell lymphoma
1.2.1 Diffuse Large B Cell Lymphoma
1.2.2 Follicular Lymphoma
1.2.3 Mantle Cell Lymphoma
1.2.4 Burkitt Lymphoma
1.3 Stages of…
